How to Find the Right Oral Solid Dose CDMO

Oral solid dose manufacturing is mature, widely available, and still highly project-specific.

A sponsor searching for tablet or capsule manufacturing will find plenty of options.

The harder part is determining which facilities actually fit the formulation and process.

One CDMO may specialize in early formulation work and small clinical batches. Another may be designed for large commercial tablet production. Some support challenging compounds, specialized coatings, or particular manufacturing technologies.

An oral solid dose CDMO develops or manufactures pharmaceutical products such as tablets and capsules.

Depending on the provider, services may include:

• preformulation
• formulation development
• granulation
• blending
• compression
• encapsulation
• coating
• analytical development
• stability testing
• GMP manufacturing
• packaging
• clinical supply
• commercial manufacturing

Some CDMOs provide an integrated development and manufacturing service.

Others focus primarily on production.

The sponsor should first define the intended dosage form.

That may include:

• tablet
• hard capsule
• another oral solid presentation

The product design influences formulation, equipment, process development, packaging, and manufacturing scale.

If the final dosage form has not yet been selected, formulation-development capability becomes especially important.

A compound may have properties that make oral formulation challenging.

Potential issues can involve:

• solubility
• stability
• flow
• compressibility
• dose
• particle properties

The sponsor may therefore need more than a company that owns a tablet press.

It may need a formulation team capable of developing a practical drug product.

Different products can require different manufacturing approaches.

Depending on the formulation, the process may involve:

• direct blending
• granulation
• milling
• drying
• compression
• encapsulation
• coating

The CDMO should have equipment and experience compatible with the proposed process.

If the process has not yet been established, the manufacturer's development experience becomes part of the decision.

A tablet formulation may require compression and potentially coating.

A capsule product may depend more heavily on powder or granule properties and the encapsulation process.

Sponsors should make sure the proposed facility supports the actual dosage form rather than treating oral solid dose capability as a single checkbox.

Dose can influence formulation and manufacturing strategy.

Very low-dose products can create different challenges from high-dose products.

If the active ingredient is highly potent, specialized containment may also be required.

Sponsors should identify these constraints early because they can materially narrow the manufacturing market.

Not every oral solid dose facility is designed for potent compounds.

Projects that require specialized containment may need:

• controlled material handling
• contained equipment
• appropriate cleaning procedures
• dedicated or segregated operations

The detailed requirements should be established by qualified technical and safety teams.

During sourcing, sponsors should determine whether the proposed facility appears equipped to support the compound.

Some tablet products require coating for:

• protection
• release characteristics
• appearance
• handling
• other formulation objectives

If coating is part of the product design, sponsors should confirm that the proposed facility has the relevant equipment and experience.

A CDMO with strong tablet compression capabilities may not necessarily offer every coating technology.

Some oral products are designed to release the active ingredient in a particular way.

These programs can require more specialized formulation and manufacturing expertise.

If the dosage form involves specialized release behavior, the sponsor should make sure that expertise is represented in the shortlist.

This is a good example of why simply filtering for “tablet manufacturing” may not be enough.

Oral solid dose programs may require analytical methods related to:

• assay
• content uniformity
• dissolution
• impurities
• stability
• other product-specific attributes

The sponsor should understand whether these methods already exist or need development.

Analytical support can be particularly important while formulation work is still underway.

A Phase I program may need relatively small batch sizes and flexibility.

Commercial manufacturing may involve:

• larger batches
• validated processes
• higher-throughput equipment
• packaging operations
• long-term supply planning

Sponsors should determine whether the CDMO fits the current stage and whether it can support future growth if that matters to the strategy.

Oral solid dose manufacturing often connects directly to packaging.

Depending on the product, that might involve bottles, blister packs, or other presentations.

Sponsors should understand:

• whether packaging is internal
• where it takes place
• what formats are available
• how packaging affects release timing

A manufacturer that produces the tablets but relies on another provider for packaging creates an additional handoff to manage.

Large oral solid dose CDMOs may operate several manufacturing sites.

Facilities can differ in:

• dosage forms
• equipment
• batch sizes
• containment
• packaging
• regulatory history

The sponsor should identify the site proposed for the program before relying heavily on company-level claims.

Facility-level inspection history can provide useful context during preliminary diligence.

Where relevant, sponsors may review available FDA Form 483 information.

Regulatory history should inform questions rather than replace formal quality qualification.

Pharma Connect Navigator helps sponsors search for manufacturing partners based on structured program requirements.

A sponsor can define development stage, manufacturing capabilities, scale, regulatory needs, project timing, geography, budget, and support requirements.

PCN helps identify potentially relevant CDMO companies and facilities and provides a structured way to compare project fit.

Teams can investigate available capabilities, equipment, facility information, and regulatory context before deciding which oral solid dose manufacturers appear worth contacting.

Detailed formulation feasibility and current manufacturing availability should be confirmed directly with the CDMO.